Navigation Links
Targeted therapy reactivates 'guardian of the genome' in resistant cancer
Date:11/15/2010

It is common for cancer cells to find some way to disarm p53, also known as "guardian of the genome" due to its action in preventing defective cells from dividing. "The critical importance of the protective function of p53 is underscored by the diversity of molecular strategies employed by cancer cells to subvert p53 activity, such as overexpression of antagonistic proteins like HDM2 and HDMX," explains senior study author Dr. Loren D. Walensky from Harvard Medical School. "Restoration of p53 activity remains an important goal in the quest for more effective cancer therapeutics."

Previous work demonstrated that selective inhibition of HDM2 restored p53 function in cancer cells. However, these results were often compromised by expression of HDMX. In an earlier study, Dr. Walensky and colleagues described the generation of "stapled" peptides designed to resemble the section of p53 that interacts with HDM2. When biochemical and structural studies revealed that HDM2 and HDMX engage the same region of p53, the researchers examined whether the most effective engineered HDM2 inhibitor (SAH-p53-8) could also interfere with HDMX and how this interaction might influence the p53 activity.

The SAH-p53-8 compound was even more effective at targeting HDMX and effectively blocked formation of the inhibitory p53-HDMX complex, thereby restoring the p53 pathway and reducing tumor cell viability. Importantly, when SAH-p53-8 was delivered intravenously to mice with HDMX-expressing cancer, p53 activity was increased and tumor growth was suppressed.

"We found that targeting HDMX overcame HDMX-mediated p53 suppression and resistance to selective HDM2 inhibition, while dual targeting of HDM2 and HDMX maximized therapeutic reactivation of the p53 tumor suppressor pathway in cancers that express both protein antagonists and retain functional p53," concludes Dr. Walensky. "Importantly, monitoring cellular levels of p53-HDMX complex may be useful for predicting cancer cell susceptibility to HDMX inhibition and determining the efficacy of HDM2 inhibitor-mediated p53 restoration, which forms the basis for enhancing the therapeutic impact of dual HDM2/HDMX targeting in resistant cancers."


'/>"/>

Contact: Elisabeth N. Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. UCI non-small cell lung cancer study highlights advances in targeted drug therapy
2. People with specific kind of lung cancer respond to new targeted treatment
3. Targeted radiation therapy minimizes GI side effects for prostate cancer patients, Penn study shows
4. Highly targeted radiation technique minimizes side effects of prostate cancer treatment
5. Sexual issues a major concern for cancer patients taking new targeted drugs
6. Targeted therapy promising for HER2-positive metastatic breast cancer
7. Evaluation of targeted therapy in ovarian cancer
8. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
9. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. Targeted therapy triggers complex mechanism of resistance
11. Synthetic lethality strategy improves molecularly targeted cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... that the company will provide alerting technology to Central Illinois Health Information ... $1.7 million in federal funds as the sole sub-recipient participating with the ...
(Date:12/5/2016)... , ... December 05, 2016 , ... Dr. Barry M. ... Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium ... the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is ...
(Date:12/5/2016)... ... December 05, 2016 , ... Florida Hospital has named Robin ... Region. McGuinness brings experience in executive leadership and clinical practice, as well as ... In her new role, that officially begins December 12, 2016, she will set ...
(Date:12/5/2016)... Franklin Lakes, NJ (PRWEB) , ... December 05, ... ... the recording studio teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” ... Jamie Foxx, Kelly Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus ...
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves come ... buy neoprene knee sleeves for lifting and any sport that requires knee ... two main aspects to provide a higher quality knee sleeve performance. Firstly it is ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)...  Wellbridge Health and Gateway Health proudly announce a dynamic ... and Medicaid plan members with specific high risk needs. ... of this group of consumers, Wellbridge combines technology and population ... insight into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... 2016 Eisai Inc. announced today new analyses ... Meeting of the American Epilepsy Society (AES). ... an adjunctive therapy for the treatment of partial onset ... primary generalized tonic-clonic seizures (PGTC) in patients with epilepsy ... see Important Safety Information for FYCOMPA, including Boxed WARNING ...
Breaking Medicine Technology: